What Hizentra treats
Hizentra is a subcutaneous immunoglobulin (SCIG) therapy used to treat primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP). It helps boost the immune system in patients who cannot produce sufficient antibodies and reduces relapse risk in patients with CIDP. Hizentra allows for flexible, at-home self-administration and consistent immune support.
Benefits of Hizentra
Patients using Hizentra may experience:
- Fewer infections and stronger immune protection in PI
- Reduced relapse risk and improved stability in CIDP
- Flexible, self-administered dosing at home
- Fewer systemic side effects compared to IVIG
- Steady IgG levels with routine dosing
Hizentra improves patient independence while delivering powerful, ongoing immune support.
Possible Side Effects of Hizentra
Hizentra is generally well-tolerated. Common side effects include:
- Local injection site reactions (swelling, redness, itching)
- Headache
- Fatigue
- Nausea
- Cough or sore throat
Rare but serious risks may include:
- Severe allergic reactions
- Aseptic meningitis
- Blood clots
- Kidney dysfunction (more common in patients at risk)
Patients should be trained on proper self-administration and monitored regularly by their healthcare provider.
How infusion works at Prime
Hizentra is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Hizentra, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Hizentra Work?
Hizentra is made from human plasma and contains a high concentration of immunoglobulin G (IgG) antibodies. These antibodies help protect against infections in immunodeficient patients. In CIDP, Hizentra is believed to help modulate the immune response and prevent damage to the peripheral nerves. The medication is administered under the skin (subcutaneously), typically once a week or as directed.
Who is Hizentra For?
Hizentra is approved for:
- Adults and children with primary immunodeficiency (PI), including conditions such as CVID (common variable immunodeficiency) and XLA (X-linked agammaglobulinemia)
- Adults with CIDP to help maintain functional abilities and reduce the frequency of relapses
It is ideal for patients who prefer or require home-based therapy with fewer clinic visits.